OA: Should we continue intra-peritoneal chemotherapy in advanced ovarian cancer patients? Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, November 27, 2016

OA: Should we continue intra-peritoneal chemotherapy in advanced ovarian cancer patients?



open access (pdf)
Sept 17, 2016

Integrative Cancer Science and Therapeutics
 Integr Cancer Sci Therap, 2016
 Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, USA

Abstract
Ovarian cancer has the highest mortality of all gynecologic malignancies in the United States. Ovarian cancer is often diagnosed at advanced stage. Optimal
cytoreduction, followed by intravenous chemotherapy consisting of platinum taxol containing agents represents the mainstay of ovarian cancer therapy. The
introduction of intraperitoneal chemotherapy utilized a novel route of administration showing promise in treating ovarian cancer both in vitro studies and clinical trials. Currently, in gynecologic oncology practice, the efficacy and toxicity of intraperitoneal chemotherapy is not yet widely agreed upon. The major clinical trials and future therapies utilizing intraperitoneal chemotherapy will be review here.


0 comments :

Post a Comment

Your comments?